Post Profile






Roche lung cancer drug success adds to pressure on Bristol

COPENHAGEN (Reuters) - Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb's dominant position in the field.
read more

share

Related Posts


Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer

Health : Medical News Today

Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says: "This study suggests that patients with HER2 positive advanced breast cancer who are no longer responding to Herceptin or chemotherapy may benefit ...

New Study Explores Immune System Stimulation In Battle Against HER-2/neu Positive Breast Cancer

Health : Medical News Today

The Mayo Clinic is excited to announce a Phase I study of a new therapeutic vaccine in HER-2/neu positive breast cancer patients in the fourth quarter of 2011. To understand the importance of this development, the HER-2/neu and the ...

Afatinib shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

Health : Medical News Today

Data from the LUX-Lung clinical trial programme, investigating afatinib in patients with advanced non-small cell lung cancer (NSCLC), have been published in the Journal of Clinical Oncology. These data include results from the pivot...

Endocyte Announces Positive Interim Results From Phase II Clinical Trial Of EC145 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Health : Medical News Today

Endocyte Inc. has announced positive interim results from an ongoing Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC). The single arm Phase II study is designed to evaluate treatment with...

Radiation Plus Chemotherapy Provides Long-Term Positive Results for Head and Neck Cancer Patients

Health : Newswise Medical News

A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to show posi...

Comments


Copyright © 2016 Regator, LLC